Following the revelation of the death of a 6-year-old girl after being treated with “the world's first brain gene editing” in late July, Huida Gene, a gene therapy company headquartered in Shanghai, revealed that in August 2025, in the first human clinical trial for Duchenne muscular dystrophy, a high-dose group subject unfortunately passed away after receiving HG302. The cause of death of the subject was “acute respiratory distress syndrome after receiving systemic administration of a viral vector associated with high adrenal doses”. In just half a month, the two child deaths that occurred in 2025 were made public one after another, all pointing to possible risky risks in the clinical trials initiated by the researchers in pursuit of “world firsts.” A number of industry experts said that these two unfortunate incidents revealed that some domestic IIT tests are progressing too fast, risk awareness is insufficient, and compliance is insufficient.